Related Experiment Videos
Cefotaxime therapy for patients with osteomyelitis and septic arthritis
Abstract:
Cefotaxime, a new cephalosporin, was evaluated for efficacy and safety in the treatment of 52 patients with serious bone and joint infections. For five of these patients therapy could not be evaluated. Diagnosis of osteomyelitis or septic arthritis was made on the basis of clinical and roentgenographic evidence of infection. The diagnosis of a bone infection was confirmed by either a positive culture of a bone biopsy or of blood in combination with a positive bone scan or roentgenogram. The diagnosis of a joint infection was confirmed by a positive culture of joint aspirate samples. Osteomyelitis was arrested in 93% (15 of 16 patients) of cases of acute osteomyelitis, 89% (24 of 27 patients) of cases of chronic osteomyelitis, and 100% (4 of 4 patients) of cases of septic arthritis. Follow-up ranged from 0-17 months after completion of cefotaxime therapy. Laboratory monitoring revealed positive direct Coombs' test (six patients), neutropenia less than 1,000 polymorphonuclear leukocytes (two patients), macular rash (two patients), phlebitis (two patients), and pseudomembranous colitis (one patient). It is concluded that cefotaxime is a useful and safe antibiotic for the treatment of osteomyelitis and septic arthritis.
Insights
Cefotaxime effectively treated serious bone and joint infections, including osteomyelitis and septic arthritis, with high arrest rates. This new cephalosporin demonstrated a favorable safety profile in patients.
Area of Science:
- Infectious Diseases
- Pharmacology
- Orthopedics
Background:
- Serious bone and joint infections, such as osteomyelitis and septic arthritis, require effective antimicrobial therapy.
- New antibiotics are continuously evaluated for improved efficacy and safety in treating complex infections.
Purpose of the Study:
- To evaluate the efficacy and safety of cefotaxime in treating patients with serious bone and joint infections.
- To determine the treatment outcomes for osteomyelitis and septic arthritis using cefotaxime.
Main Methods:
- A study involving 52 patients diagnosed with serious bone and joint infections.
- Infection confirmation through clinical, roentgenographic, and microbiological evidence (bone biopsy, blood culture, joint aspirate).
- Assessment of cefotaxime efficacy based on infection arrest rates and patient follow-up (0-17 months).
Main Results:
- High arrest rates for osteomyelitis: 93% in acute and 89% in chronic cases.
- 100% arrest rate observed in cases of septic arthritis.
- Reported adverse events included positive direct Coombs' test, neutropenia, rash, phlebitis, and pseudomembranous colitis.
Conclusions:
- Cefotaxime is a useful and safe antibiotic for treating osteomyelitis and septic arthritis.
- The study supports the clinical utility of cefotaxime in managing severe bone and joint infections.
- Further monitoring confirmed the safety profile of cefotaxime in this patient cohort.